Monitor for the definitive proxy statement (DEF 14A) which should contain specific vote items and management proposals. The DEFA14A itself is a procedural solicitation filing with no standalone trading signal.
IMA drugs
IMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $5.66entry
- T+1 · 7mo ago +0.97%α +1.31% · $5.72
- T+5 · 6mo ago −6.54%α −8.88% · $5.29
- T+20 · 6mo ago −3.36%α −8.62% · $5.47
- T+60 · 4mo ago +1.77%α −1.30% · $5.76
Price Chart
How similar events traded
Executive Summary
ImageneBio filed a DEFA14A (definitive additional proxy soliciting materials) on April 30, 2026. The filing is marked as filed by the registrant and checks the box for 'Definitive Additional Materials' and 'Soliciting Material Pursuant to 240.14a-12', indicating management is actively soliciting shareholder votes. The document content is largely boilerplate and contains no specific financial figures, vote details, or activist demands.
Key Facts
- Filed DEFA14A on 2026-04-30 as definitive additional proxy soliciting materials
- Filed by the registrant (management), not a dissident party
- Document text is largely boilerplate with no specific financial data, vote items, or activist demands
- Company has a $63M market cap and 71% analyst bullish consensus
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- No substantive financial or voting details in this filing
- Historical poor performance on IMA filings suggests limited predictive value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-018272 |
| Document: 0001140361-26-018272-index-headers.html | 0001140361-26-018272 |
| Document: 0001140361-26-018272-index.html | 0001140361-26-018272 |
| Document: 0001140361-26-018272.txt | 0001140361-26-018272 |
Track record
10 reports on IMA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Viewing Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers